AP Nademanee

1.9k total citations
27 papers, 1.4k citations indexed

About

AP Nademanee is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, AP Nademanee has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 9 papers in Public Health, Environmental and Occupational Health and 8 papers in Oncology. Recurrent topics in AP Nademanee's work include Hematopoietic Stem Cell Transplantation (22 papers), Acute Myeloid Leukemia Research (14 papers) and Acute Lymphoblastic Leukemia research (9 papers). AP Nademanee is often cited by papers focused on Hematopoietic Stem Cell Transplantation (22 papers), Acute Myeloid Leukemia Research (14 papers) and Acute Lymphoblastic Leukemia research (9 papers). AP Nademanee collaborates with scholars based in United States. AP Nademanee's co-authors include GM Schmidt, MR O’Donnell, PM Parker, DS Snyder, SJ Forman, G. Schmidt, Margaret O’Donnell, J. L. Fahey, KG Blume and JL Fahey and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

AP Nademanee

27 papers receiving 1.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
AP Nademanee 1.1k 510 355 182 163 27 1.4k
MR O’Donnell 982 0.9× 405 0.8× 358 1.0× 208 1.1× 107 0.7× 25 1.4k
PM Parker 833 0.8× 374 0.7× 383 1.1× 160 0.9× 64 0.4× 21 1.2k
J Cahn 1.2k 1.1× 364 0.7× 392 1.1× 216 1.2× 282 1.7× 70 1.6k
D I Marks 1.2k 1.1× 505 1.0× 387 1.1× 241 1.3× 110 0.7× 47 1.6k
Francis Witz 1.3k 1.2× 759 1.5× 414 1.2× 430 2.4× 415 2.5× 54 2.0k
Keiko Yumura‐Yagi 605 0.6× 383 0.8× 332 0.9× 155 0.9× 201 1.2× 49 1.2k
Yasunori Ueda 1.1k 1.0× 699 1.4× 410 1.2× 272 1.5× 147 0.9× 115 1.6k
A Iriondo 625 0.6× 190 0.4× 255 0.7× 130 0.7× 166 1.0× 45 1.0k
RH Herzig 884 0.8× 341 0.7× 254 0.7× 238 1.3× 98 0.6× 17 1.1k
Boglarka Gyurkocza 1.3k 1.2× 511 1.0× 377 1.1× 244 1.3× 282 1.7× 68 1.7k

Countries citing papers authored by AP Nademanee

Since Specialization
Citations

This map shows the geographic impact of AP Nademanee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AP Nademanee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AP Nademanee more than expected).

Fields of papers citing papers by AP Nademanee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AP Nademanee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AP Nademanee. The network helps show where AP Nademanee may publish in the future.

Co-authorship network of co-authors of AP Nademanee

This figure shows the co-authorship network connecting the top 25 collaborators of AP Nademanee. A scholar is included among the top collaborators of AP Nademanee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AP Nademanee. AP Nademanee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Robert, Paul Frankel, Leslie Popplewell, et al.. (2015). A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 100(3). 357–362. 61 indexed citations
2.
Vanderwalde, Ari M., Liton Francisco, Saro H. Armenian, et al.. (2012). Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. Leukemia. 27(5). 1139–1145. 33 indexed citations
3.
Pullarkat, Vinod, Marilyn L. Slovak, Andrew Dagis, et al.. (2009). Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Annals of Oncology. 20(12). 2000–2006. 11 indexed citations
4.
Popplewell, Leslie, et al.. (2004). Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants.. Blood. 104(11). 4563–4563. 2 indexed citations
5.
6.
Molina, A., Leslie Popplewell, A. Kashyap, & AP Nademanee. (2000). Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center.. PubMed. 317–42. 8 indexed citations
7.
Long, GD, M Amylon, Keith Stockerl‐Goldstein, et al.. (1997). Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.. PubMed. 3(6). 324–30. 35 indexed citations
8.
Stein, Anthony S., Margaret O’Donnell, GM Schmidt, et al.. (1996). In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.. Journal of Clinical Oncology. 14(8). 2206–2216. 46 indexed citations
9.
O’Donnell, Margaret, G D Long, Pablo Parker, et al.. (1995). Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.. Journal of Clinical Oncology. 13(12). 2973–2979. 51 indexed citations
10.
11.
O’Donnell, Margaret, G. Schmidt, Bernard Tegtmeier, et al.. (1994). Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.. Journal of Clinical Oncology. 12(4). 827–834. 131 indexed citations
12.
13.
Forman, Stephen J., G. Schmidt, AP Nademanee, et al.. (1991). Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia.. Journal of Clinical Oncology. 9(9). 1570–1574. 60 indexed citations
14.
Chao, NJ, SJ Forman, GM Schmidt, et al.. (1991). Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood. 78(8). 1923–1927. 6 indexed citations
15.
Chao, NJ, SJ Forman, GM Schmidt, et al.. (1991). Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood. 78(8). 1923–1927. 94 indexed citations
16.
Nademanee, AP, Stephen J. Forman, GM Schmidt, et al.. (1987). Allogeneic bone marrow transplantation for high risk non-hodgkin's lymphoma during first complete remission. Annals of Hematology. 55(1). 11–18. 11 indexed citations
17.
O'Donnell, M R, AP Nademanee, D. Snyder, et al.. (1987). Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes.. Journal of Clinical Oncology. 5(11). 1822–1826. 74 indexed citations
18.
Blume, Karl G., Stephen J. Forman, David S. Snyder, et al.. (1987). ALLOGENEIC BONE MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA DURING FIRST COMPLETE REMISSION. Transplantation. 43(3). 389–392. 66 indexed citations
19.
Forman, SJ, MR O’Donnell, AP Nademanee, et al.. (1987). Bone marrow transplantation for patients with Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood. 70(2). 587–588. 6 indexed citations
20.
Forman, SJ, AP Nademanee, JL Fahey, et al.. (1983). Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood. 61(3). 439–442. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MR O’Donnell Breakdown of academic impact, for papers by PM Parker Breakdown of academic impact, for papers by J Cahn Breakdown of academic impact, for papers by D I Marks Breakdown of academic impact, for papers by Francis Witz Breakdown of academic impact, for papers by Keiko Yumura‐Yagi Breakdown of academic impact, for papers by Yasunori Ueda Breakdown of academic impact, for papers by A Iriondo Breakdown of academic impact, for papers by RH Herzig Breakdown of academic impact, for papers by Boglarka Gyurkocza
Rankless by CCL
2026